Full-Time

Sr. Scientist

Upstream Polysaccharide Process Development

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$150k - $169kAnnually

+ Equity Component + Comprehensive Benefits

Senior

San Carlos, CA, USA

Position requires onsite presence in San Carlos, CA.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • PhD in Chemical/Biochemical Engineering, Biotechnology, or similar degree with 3+ years of relevant industry experience, or MS with 6+ years of relevant industry experience.
  • Expertise in upstream process development, scale-down, scale-up, and technology transfer of microbial fermentation, and vaccine production processes.
  • Cell banking expertise, colony selection and genetic analysis of recombinant strains.
  • Hands-on experience with fermenters, microbial media, and process analytical technologies.
  • Strong knowledge in fermentation development utilizing multi-variate development experiments (e.g. Design of Experiments) for polysaccharide production using microorganisms in lab and pilot-scale fermenters.
  • Experience working with BSL2 organisms, *Streptococcus pneumoniae* and *Escherichia coli* are a plus.
  • Excellent communication, presentation, and interpersonal skills.
  • Ability to work independently and as part of a team in a fast-paced environment.
  • Proficient in data analysis and statistical software such as JMP or Design Expert.
Responsibilities
  • Design, execute, and analyze experiments for upstream polysaccharide fermentation processes and scale-up of microbial fermentation, and vaccine production processes.
  • Design experiment to optimize fermenter process parameters such as media, feed, pH, temperature, dissolved oxygen, agitation, and aeration to enhance product yield, quality, and consistency.
  • Lead early and late-stage upstream process development for polysaccharide vaccine production.
  • Lead and perform fermenter studies including kLa/OTR, scale-up and scale-down processes.
  • Evaluate and implement new technologies and methods to improve upstream process performance and robustness.
  • Prepare and review technical reports, SOPs, batch records, and regulatory documents.
  • Lead and supervise junior scientists and research associates and provide technical guidance and troubleshooting.
  • Present and communicate scientific data and results to internal and external stakeholders.
  • Collaborate effectively with downstream, analytical, and manufacturing teams within polysaccharide development and manufacturing team to ensure seamless technology transfer and process integration.
  • Be an outstanding teammate and collaborate across groups both internal and external (CMO) to Vaxcyte.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA for adult use. Vaxcyte employs advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while eliciting a strong immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial infections on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

23%

1 year growth

61%

2 year growth

132%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.

Help us improve and share your feedback! Did you find this helpful?